Advances in mechanisms of resistance to aromatase inhibitors

Expert Review of Anticancer Therapy

Volumn 14, Issue 4, 2014, Pages 381-393

  Chumsri, Saranya ^a   Schech, Amanda ^a   Chakkabat, Chakkapong ^b   Sabnis, Gauri ^a   Brodie, Angela ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

aromatase inhibitors; breast cancer; CDK4 6 inhibitor; everolimus; fulvestrant; growth factor receptor pathways; HER2; mTOR inhibitors; resistance to aromatase inhibitors

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE 6 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; DASATINIB; ENTINOSTAT; EVEROLIMUS; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; LETROZOLE; PALBOCICLIB; PLACEBO; PYRIDOGLUTETHIMIDE; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VOROZOLE; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE REGULATION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TOR SERINE-THREONINE KINASES;

EID: 84896945490     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.882233     Document Type: Review

References (92)

1. Beatson CT. On treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7
2. Love RR, Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 2002;94(19):1433-4
3. Allen E, Doisy EA. An ovarian hormone: preliminary report on its localization, extraction, and partial purification and actions in test animals. J Am Med Assoc 1923;81:819
4. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9(6):1980-9
5. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007; 72(1):7-25
6. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86(7):527-37
7. Jordan VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 1995;35:195-211
8. Brodie AM, Schwarzel WC, Shaikh AA, Brodie HJ. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17- dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 1977;100(6):1684-95
9. Thompson EA Jr, Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 1974; 249(17):5364-72
10. Chen SA, Besman MJ, Sparkes RS, et al. Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA 1988; 7(1):27-38
11. Chumsri S, Howes T, Bao T, et al. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011; 125(1-2):13-22
12. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359(9324):2131-9
13. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11(12):1135-41
14. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26(30):4875-82
15. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19(10): 2596-606
16. Brodie AM, Garrett WM, Hendrickson JR, et al. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4- acetoxy-4-androstene-3,17- dione and sustained effects in vivo. Steroids 1981; 38(6):693-702
17. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92(9):2247-58
18. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18(22):3758-67
19. Mouridsen HT. Aromatase inhibitors in advanced breast cancer. Semin Oncol 2004; 31(6 Suppl 12):3-8
20. Joel PB, Traish AM, Lannigan DA. Estradiol-induced phosphorylation of serine in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 1998;273(21): 13317-23
21. Macedo LF, Sabnis G, Brodie A. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors. Cancer 2008;112(3 Suppl):679-88
22. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270(5241): 1491-4
23. Paridaens R, Dirix L. First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients: A randomized phase III trial of the EORTC Breast Group. 2004;23:6
24. Macedo LF, Sabnis G, Brodie A. Aromatase inhibitors and breast cancer. Ann NY Acad Sci 2009;1155:162-73
25. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/expression status. Cancer Res 2003; 63(19):6523-31
26. Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 2008;68(9): 3516-22
27. Chen D, Washbrook E, Sarwar N, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002;21(32):4921-31
28. Johnston SR. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 2009;9(Suppl 1): S28-36
29. Wu RC, Qin J, Yi P, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell 2004;15(6):937-49
30. Font De Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20(14):5041-7
31. Sabnis GJ, Macedo LF, Goloubeva O, et al. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 2008; 68(12):4518-24
32. Thurlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997;33(11): 1767-73
33. Carlini P, Frassoldati A, De Marco S, et al. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? Ann Oncol 2001;12(11):1539-43
34. Miller WR, Bartlett J, Brodie AM, et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008;13(8):829-37
35. Geisler J, Johannessen DC, Anker G, Lonning PE. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Eur J Cancer 1996;32A(5):789-92
36. Harper-Wynne C, English J, Meyer L, et al. Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. Br J Cancer 1999;81(2):316-22
37. Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69(6):471-7
38. Zilembo N, Bajetta E, Bichisao E, et al. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. Biomed Pharmacother 2004;58(4):255-9
39. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26(10):1664-70
40. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28(30):4594-600
41. Sabnis G, Schayowitz A, Goloubeva O, et al. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009;69(4):1416-28
42. Gilani RA, Kazi AA, Shah P, et al. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 2012;135(3): 681-92
43. Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005;104(2):257-63
44. Lipton A, Ali S, Leitzel K. HER-2 protein expression predicts response to trastuzumab in FISH-positive patients with metastatic breast cancer. Oral Presentation 2008; abstract #32
45. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102(1):43-9
46. Mackey J, Kaufman B, Clemens M. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006;100(Suppl 1): abstract 3
47. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27(33):5538-46
48. Sabnis G, Goloubeva O, Jelovac D, et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 2007;13(9):2751-7
49. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64(1):36-42
50. Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998;30(5):2192-4
51. Atkins MB, Yasothan U, Kirkpatrick P. Everolimus. Nat Rev Drug Discov 2009; 8(7):535-6
52. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30(22):2718-24
53. Hortobagyi G, Piccart M, Rugo H, et al. Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial. Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial 2011
54. Piccart-Gebhart M, Noguchi S, Pritchard K, et al. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial 2012
55. Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31(2):195-202
56. Chow L, Sun Y, Jassem J. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. 2006;23(10):2526-35
57. Villarreal-Garza C, Cortes J, Andre F, Verma S. mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol 2012
58. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10(11):868-80
59. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008;1:20
60. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4(6):470-80
61. Boyce BF, Yoneda T, Lowe C, et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992; 90(4):1622-7
62. Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur J Cancer 2010;46(12): 2187-95
63. Morgan L, Gee J, Pumford S, et al. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 2009;8(16):1550-8
64. Hiscox S, Morgan L, Green TP, et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97(3):263-74
65. Hiscox S, Jordan NJ, Morgan L, et al. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 2007; 24(3):157-67
66. Chen Y, Guggisberg N, Jorda M, et al. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 2009;15(10):3396-405
67. Mcbryan J, Theissen SM, Byrne C, et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res 2012;72(2):548-59
68. Llombart A, Ravaioli A, Strauss L, et al. Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/PR-Positive Breast Cancer [BMS CA180-261 Study]. Randomized Phase II Study of Dasatinib vs Placebo in Addition to Exemestane in Advanced ER/ PR-Positive Breast Cancer [BMS CA180-261 Study]
69. Sabnis GJ, Kazi A, Golubeva O, et al. Effect of selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Res Treat 2013;138(3):699-708
70. Sabnis G, Goloubeva O, Gilani R, et al. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment. Mol Cancer Ther 2010;9(1): 46-56
71. Sabnis G, Kazi A, Goloubeva O, Brodie A. HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through modulation of Her-2. Cancer Res 2010; 70(Suppl 2):24
72. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18(5):601-7
73. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013;31(17):2128-35
74. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
75. Chung EJ, Lee S, Sausville EA, et al. Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. Ann Clin Lab Sci 2005;35(4):397-406
76. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52
77. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011;13(6):221
78. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100(14):8418-23
79. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869-74
80. Sotiriou C, Neo SY, Mcshane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100(18):10393-8
81. Ruiz-Borrego M, Moreno A, Salvador J, et al. Different treatment benefit for luminal A and luminal B advanced breast carcinomas receiving aromatase inhibitors. Cancer Res 2009;69(24 Suppl 3):5141
82. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355(6):560-9
83. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27): 2817-26
84. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34
85. Dunbier AK, Ghazoui Z, Anderson H, et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 2013;19(10): 2775-86
86. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367(5):435-44
87. Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012;30(16):1919-25
88. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23(18):4215-24
89. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35(14):1886-94
90. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8(8):2127-33
91. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11(5):R77
92. Finn R, Crown J, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/ inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER +/HER2- advanced breast cancer (BC). Cancer Res 2012;72(24 Suppl 3):S1-6